Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2022, Vol. 27 ›› Issue (4): 442-445.doi: 10.12092/j.issn.1009-2501.2022.04.014

Previous Articles     Next Articles

Angiotensin receptor neprilysin inhibitor in elderly with hypertension

KUAI Zheng1, ZHANG Xiaoyi1, ZOU Yunzeng2   

  1. 1 Department of Geriatrics, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 2 Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institute of Biomedical Sciences, Fudan University, Shanghai 200032, China
  • Online:2022-04-26 Published:2022-05-17

Abstract:

Angiotensin receptor/neprilysin inhibitor (ARNI) is a novel combination drug that is a dual inhibitor of angiotensin receptor and neprilysin. In June 2021, the National Medical Products Administration approved ARNI for hypertension indications. This review provides an update of current literature on ARNI in elderly hypertension.

Key words: angiotensin receptor neprilysin inhibitor, LCZ696, elderly, hypertension

CLC Number: